An new medicine to treat obesity is currently showing promising effects when used to treat teenagers from weight gain following successful studies on adults and subsequent US Food and Drug Authority approval last year.
According to “New Atlas,” which cited “The New England Journal of Medicine,” treatment also promotes benefits that improve a few cardiovascular health indicators.
In 2017, the aforementioned product received approval as a type 2 diabetes medication, but it also demonstrated encouraging results in the area of weight loss. The drug works by simulating the chemical composition of a hormone in the body that works on the appetite control center in the brain to reduce the feeling of hunger, and a small study in 2017 showed that it led to weight loss in a group of 28 people with obesity.
This was followed by an experiment that included more than 2000 obese people, who received weekly injection of the drug, and they were placed in weight loss programs while taking less calories and an increase in physical activity. The average weight loss in this group was 15.3 kg, with an average BMI index fall of 5.54 percent, as well as a decline in risk factors for diabetes and heart disease.
In June of last year, the FDA subsequently approved the use of the medication as a treatment for adult obesity.
The consequences on adolescents remain unknown even as research concerning the anti-obesity advantages in adults continues to mount. Therefore, another study was conducted on 201 people between the ages of 12 and 18 years of weight gain or obesity, and they were given weekly injections either from the re -employed drug or an imaginary drug and advice was provided at the same time on nutrition and physical activity.
At least 75% of the individuals lost 5% of their body weight after 68 weeks, compared to only 17% of those who took an imagined medicine. The BMI of the actual real estate group decreased on average by 16. 1%, while the BMI of the hypothetical medication group grew on average by 0. 6%. Scientists have also observed an improvement in the factors of cardiovascular risk, including the circumference of the waist and cholesterol and control of blood sugar. ” The outcomes are astounding.
According to Silva Arslanian, principal researcher at the University of Pittsburgh, the average drop in body mass index is comparable to a loss of roughly 18 kg for a person with a length of 165 cm and a weight of 109 kg.
Amazing studies. Diabetes medication that addresses teen obesity
About Author
